Healthcare - Biotechnology - NASDAQ - US
$ 1.1
0 %
$ 307 M
Market Cap
-1.39
P/E
INCOME STATEMENT
130 K
REVENUE
-245 M
OPERATING INCOME
-235 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Lyell Immunopharma, Inc.
| Revenue | 130 K |
| Cost Of Revenue | 0 |
| Gross Profit | 130 K |
| Operating Expenses | 247 M |
| Operating Income | -245 M |
| Other Expenses | -10.9 M |
| Net Income | -235 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| REVENUE | |||||
| Revenue | 0.1 | 84.7 | 10.7 | 7.8 | 0.7 |
| GROSS PROFIT | |||||
| Cost Of Revenue | 0 | 16.5 | 14.5 | 7.5 | 0 |
| Gross Profit | 0.1 | 68.2 | (3.9) | 0.3 | 0.7 |
| OPERATING INCOME | |||||
| Operating Expenses | 247.1 | 276.5 | 225.4 | 219.7 | 102.7 |
| Selling, General and Administrative Expenses | 67.0 | 117.3 | 89.1 | 46.9 | 39.2 |
| Research and Development Expenses | 182.9 | 159.2 | 138.7 | 182.2 | 63.6 |
| Operating Income | (245.5) | (183.1) | (214.8) | (211.9) | (102.1) |
| PRE-TAX INCOME | |||||
| Interest Income Expense | 0 | 0 | 0 | 0 | 0 |
| Total Other Income | 10.9 | 3.8 | (36.7) | 7.5 | (27.3) |
| Pre-Tax Income | (234.6) | (183.1) | (250.2) | (204.5) | (129.4) |
| NET INCOME | |||||
| Tax Provision | 0 | (178.4) | 35.3 | (5.9) | (8.1) |
| Net Income | (234.6) | (4.8) | (285.5) | (198.5) | (121.3) |
| EPS | 0.93 | 0.0192 | 1.18 | 0.81 | 0.49 |